{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T10:09:37Z","timestamp":1746785377389},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00347-023-01880-y","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T12:02:11Z","timestamp":1686830531000},"page":"779-790","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Okul\u00e4res Schleimhautpemphigoid","Ocular mucous membrane pemphigoid"],"prefix":"10.1007","volume":"120","author":[{"given":"R.","family":"Ya\u00efci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Geerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"1880_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/archderm.138.3.370","volume":"138","author":"LS Chan","year":"2002","unstructured":"Chan\u00a0LS, Razzaque Ahmed\u00a0A, Anhalt\u00a0GJ et\u00a0al (2002) The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment and prognostic indicators. Arch Dermatol 138:370\u2013379","journal-title":"Arch Dermatol"},{"key":"1880_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1365-4362.1986.tb04544.x","volume":"25","author":"AR Ahmed","year":"1986","unstructured":"Ahmed\u00a0AR, Hombal\u00a0SM (1986) Cicatricial pemphigoid. Int J Dermatol 25:90\u201396. https:\/\/doi.org\/10.1111\/j.1365-4362.1986.tb04544.x","journal-title":"Int J Dermatol"},{"key":"1880_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/bjo.80.4.292","volume":"80","author":"MJ Elder","year":"1996","unstructured":"Elder\u00a0MJ, Bernauer\u00a0W, Leonard\u00a0J et\u00a0al (1996) Progression of disease in ocular cicatricial pemphigoid. Br J Ophthalmol 80:292\u2013296","journal-title":"Br J Ophthalmol"},{"key":"1880_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00105-017-4089-y","volume":"69","author":"MM Holtsche","year":"2018","unstructured":"Holtsche\u00a0MM, Zillikens\u00a0D, Schmidt\u00a0E (2018) Mucous membrane pemphigoid. Hautarzt 69:67\u201383. https:\/\/doi.org\/10.1007\/s00105-017-4089-y","journal-title":"Hautarzt"},{"key":"1880_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00347-008-1699-x","volume":"105","author":"E Schmidt","year":"2008","unstructured":"Schmidt\u00a0E, Meyer-Ter-Vehn\u00a0T, Zillikens\u00a0D et al (2008) Schleimhautpemphigoid mit okul\u00e4rer Beteiligung Teil I: Klinik, Pathogenese und Diagnostik. Ophthalmologe 105:285\u2013297. https:\/\/doi.org\/10.1007\/s00347-008-1699-x (quiz 298)","journal-title":"Ophthalmologe"},{"key":"1880_CR6","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","volume":"136","author":"F H\u00fcbner","year":"2016","unstructured":"H\u00fcbner\u00a0F, Recke\u00a0A, Zillikens\u00a0D et\u00a0al (2016) Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J\u00a0Invest Dermatol 136:2495\u20132498. https:\/\/doi.org\/10.1016\/j.jid.2016.07.013","journal-title":"J Invest Dermatol"},{"key":"1880_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/J.1610-0387.2008.06976.X","volume":"7","author":"F Bertram","year":"2009","unstructured":"Bertram\u00a0F, Br\u00f6cker\u00a0EB, Zillikens\u00a0D et\u00a0al (2009) Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J\u00a0Dtsch Dermatol Ges 7:434\u2013439. https:\/\/doi.org\/10.1111\/J.1610-0387.2008.06976.X","journal-title":"J Dtsch Dermatol Ges"},{"key":"1880_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02219","author":"J Lee","year":"2019","unstructured":"Lee\u00a0J, Seiffert-Sinha\u00a0K, Attwood\u00a0K et al (2019) A retrospective study of patient-reported data of bullous pemphigoid and mucous membrane pemphigoid from a\u00a0US-based registry. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.02219","journal-title":"Front Immunol"},{"key":"1880_CR9","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/jdv.17107","volume":"35","author":"N Beek","year":"2021","unstructured":"Beek\u00a0N, Weidinger\u00a0A, Schneider\u00a0SW et al (2021) Incidence of pemphigoid diseases in northern Germany in 2016\u2014first data from the Schleswig-Holstein registry of autoimmune bullous diseases. J\u00a0Eur Acad Dermatol Venereol 35:1197\u20131202. https:\/\/doi.org\/10.1111\/jdv.17107","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1880_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1525-1470.2009.01079.x","volume":"27","author":"M Kharfi","year":"2010","unstructured":"Kharfi\u00a0M, Khaled\u00a0A, Anane\u00a0R et\u00a0al (2010) Early onset childhood cicatricial pemphigoid: a case report and review of the literature. Pediatr Dermatol 27:119\u2013124. https:\/\/doi.org\/10.1111\/j.1525-1470.2009.01079.x","journal-title":"Pediatr Dermatol"},{"key":"1880_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ophtha.2003.03.001","volume":"111","author":"JE Thorne","year":"2004","unstructured":"Thorne\u00a0JE, Anhalt\u00a0GJ, Jabs\u00a0DA (2004) Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology 111:45\u201352. https:\/\/doi.org\/10.1016\/j.ophtha.2003.03.001","journal-title":"Ophthalmology"},{"key":"1880_CR12","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/eye.2012.119","volume":"26","author":"CF Radford","year":"2012","unstructured":"Radford\u00a0CF, Rauz\u00a0S, Williams\u00a0GP et\u00a0al (2012) Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom. Eye (Lond) 26:1199\u20131208. https:\/\/doi.org\/10.1038\/eye.2012.119","journal-title":"Eye (Lond)"},{"key":"1880_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/eye.2016.284","volume":"31","author":"JK Dart","year":"2017","unstructured":"Dart\u00a0JK (2017) The 2016 Bowman lecture conjunctival curses: scarring conjunctivitis 30\u00a0years on. Eye (Lond) 31:301\u2013332. https:\/\/doi.org\/10.1038\/eye.2016.284","journal-title":"Eye (Lond)"},{"key":"1880_CR14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1055\/s-0032-1328748","volume":"230","author":"A R\u00fcbsam","year":"2013","unstructured":"R\u00fcbsam\u00a0A, Klein\u00a0J, Pleyer\u00a0U (2013) Das okul\u00e4re vernarbende Pemphigoid \u2013 aktuelle Aspekte zu Klinik und Therapie einer problematischen Erkrankung. Klin Monbl Augenheilkd 230:796\u2013803. https:\/\/doi.org\/10.1055\/s-0032-1328748","journal-title":"Klin Monbl Augenheilkd"},{"key":"1880_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0161-6420(81)35069-6","volume":"88","author":"BJ Mondino","year":"1981","unstructured":"Mondino\u00a0BJ, Brown\u00a0SI (1981) Ocular cicatricial pemphigoid. Ophthalmology 88:95\u2013100. https:\/\/doi.org\/10.1016\/S0161-6420(81)35069-6","journal-title":"Ophthalmology"},{"key":"1880_CR16","first-page":"527","volume":"84","author":"CS Foster","year":"1986","unstructured":"Foster\u00a0CS (1986) Cicatricial pemphigoid. Trans Am Ophthalmol Soc 84:527\u2013663","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1880_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jtos.2019.10.010","volume":"18","author":"HS Ong","year":"2020","unstructured":"Ong\u00a0HS, Minassian\u00a0D, Rauz\u00a0S et\u00a0al (2020) Validation of a\u00a0clinical assessment tool for cicatrising conjunctivitis. Ocul Surf 18:121\u2013129. https:\/\/doi.org\/10.1016\/j.jtos.2019.10.010","journal-title":"Ocul Surf"},{"key":"1880_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ajo.2017.08.009","volume":"183","author":"MT Labowsky","year":"2017","unstructured":"Labowsky\u00a0MT, Stinnett\u00a0SS, Liss\u00a0J et\u00a0al (2017) Clinical implications of direct immunofluorescence findings in patients with ocular mucous membrane pemphigoid. Am J Ophthalmol 183:48\u201355. https:\/\/doi.org\/10.1016\/j.ajo.2017.08.009","journal-title":"Am J Ophthalmol"},{"key":"1880_CR19","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/bjo.2006.109124","volume":"91","author":"MV De Rojas","year":"2007","unstructured":"De Rojas\u00a0MV, Dart\u00a0JKG, Saw\u00a0VPJ (2007) The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol 91:1048\u20131053. https:\/\/doi.org\/10.1136\/bjo.2006.109124","journal-title":"Br J Ophthalmol"},{"key":"1880_CR20","volume-title":"AWMF-S2k-Leitlinie Diagnostik und Therapie des Schleimhautpemphigoids","author":"E Schmidt","year":"2022","unstructured":"Schmidt\u00a0E, Nast\u00a0A (2022) AWMF-S2k-Leitlinie Diagnostik und Therapie des Schleimhautpemphigoids (AWMF-Register-Nr: 013-102, 2022)"},{"key":"1880_CR21","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/JDV.17397","volume":"35","author":"H Rashid","year":"2021","unstructured":"Rashid\u00a0H, Lamberts\u00a0A, Borradori\u00a0L et\u00a0al (2021) European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European academy of dermatology and venereology\u2014part I. J\u00a0Eur Acad Dermatol Venereol 35:1750\u20131764. https:\/\/doi.org\/10.1111\/JDV.17397","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1880_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/JDV.17395","author":"E Schmidt","year":"2021","unstructured":"Schmidt\u00a0E, Rashid\u00a0H, Marzano\u00a0AV et\u00a0al (2021) European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European academy of dermatology and venereology\u2014part II. Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/JDV.17395","journal-title":"Acad Dermatol Venereol"},{"key":"1880_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1365-2133.2005.06998.x","volume":"154","author":"N Oyama","year":"2006","unstructured":"Oyama\u00a0N, Setterfield\u00a0JF, Powell\u00a0AM et\u00a0al (2006) Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol 154:90\u201398. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06998.x","journal-title":"Br J Dermatol"},{"key":"1880_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0923-1811(97)00067-4","volume":"17","author":"H Murakami","year":"1998","unstructured":"Murakami\u00a0H, Nishioka\u00a0S, Setterfield\u00a0J et\u00a0al (1998) Analysis of antigens targeted by circulating IgG and IgA autoantibodies in 50\u00a0patients with cicatricial pemphigoid. J\u00a0Dermatol Sci 17:39\u201344. https:\/\/doi.org\/10.1016\/S0923-1811(97)00067-4","journal-title":"J Dermatol Sci"},{"key":"1880_CR25","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1046\/j.1365-2133.2001.04471.x","volume":"145","author":"E Schmidt","year":"2001","unstructured":"Schmidt\u00a0E, Skrobek\u00a0C, Kromminga\u00a0A et al (2001) Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 145:778\u2013783. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04471.x","journal-title":"Br J Dermatol"},{"key":"1880_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamadermatol.2013.1434","volume":"149","author":"P Bernard","year":"2013","unstructured":"Bernard\u00a0P, Antonicelli\u00a0F, Bedane\u00a0C et al (2013) Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a\u00a0novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid. JAMA Dermatol 149:533\u2013540. https:\/\/doi.org\/10.1001\/jamadermatol.2013.1434","journal-title":"JAMA Dermatol"},{"key":"1880_CR27","unstructured":"Therapieinformationsb\u00f6gen. https:\/\/dgrh.de\/Start\/Versorgung\/Therapieinformationen\/Therapieinformationsb%C3%B6gen.html;. Zugegriffen: 8. Juni 2021"},{"key":"1880_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ophtha.2007.04.027","volume":"115","author":"VPJ Saw","year":"2007","unstructured":"Saw\u00a0VPJ, Dart\u00a0JKG, Rauz\u00a0S et\u00a0al (2007) Immunosuppressive therapy for ocular mucous membrane pemphigoid. Ophthalmology 115:253\u2013261.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2007.04.027","journal-title":"Ophthalmology"},{"key":"1880_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0161-6420(80)35272-X","volume":"87","author":"CS Foster","year":"1980","unstructured":"Foster\u00a0CS (1980) Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology 87:140\u2013150. https:\/\/doi.org\/10.1016\/S0161-6420(80)35272-X","journal-title":"Ophthalmology"},{"key":"1880_CR30","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","volume":"116","author":"S Gangaputra","year":"2009","unstructured":"Gangaputra\u00a0S, Newcomb\u00a0CW, Liesegang\u00a0TL et\u00a0al (2009) Methotrexate for ocular inflammatory diseases. Ophthalmology 116:2188\u20132198.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2009.04.020","journal-title":"Ophthalmology"},{"key":"1880_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/bjo.79.3.264","volume":"79","author":"MJ Elder","year":"1995","unstructured":"Elder\u00a0MJ, Lightman\u00a0S, Dart\u00a0JK (1995) Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol 79:264\u2013266. https:\/\/doi.org\/10.1136\/bjo.79.3.264","journal-title":"Br J Ophthalmol"},{"key":"1880_CR32","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","volume":"117","author":"SS Pujari","year":"2010","unstructured":"Pujari\u00a0SS, Kempen\u00a0JH, Newcomb\u00a0CW et\u00a0al (2010) Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 117:356\u2013365. https:\/\/doi.org\/10.1016\/j.ophtha.2009.06.060","journal-title":"Ophthalmology"},{"key":"1880_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.clim.2003.11.002","volume":"111","author":"E Letko","year":"2004","unstructured":"Letko\u00a0E, Miserocchi\u00a0E, Daoud\u00a0YJ et\u00a0al (2004) A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 111:303\u2013310. https:\/\/doi.org\/10.1016\/j.clim.2003.11.002","journal-title":"Clin Immunol"},{"key":"1880_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","volume":"147","author":"C Le Roux-Villet","year":"2011","unstructured":"Le Roux-Villet\u00a0C, Prost-Squarcioni\u00a0C, Alexandre\u00a0M et al (2011) Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 147:843\u2013849. https:\/\/doi.org\/10.1001\/archdermatol.2011.54","journal-title":"Arch Dermatol"},{"key":"1880_CR35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1517\/14712598.2015.1046833","volume":"15","author":"A R\u00fcbsam","year":"2015","unstructured":"R\u00fcbsam\u00a0A, Stefaniak\u00a0R, Worm\u00a0M et\u00a0al (2015) Rituximab preserves vision in ocular mucous membrane pemphigoid. Expert Opin Biol Ther 15:927\u2013933","journal-title":"Expert Opin Biol Ther"},{"key":"1880_CR36","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jaad.2016.01.020","volume":"74","author":"A Maley","year":"2016","unstructured":"Maley\u00a0A, Warren\u00a0M, Haberman\u00a0I et\u00a0al (2016) Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J\u00a0Am Acad Dermatol 74:835\u2013840. https:\/\/doi.org\/10.1016\/j.jaad.2016.01.020","journal-title":"J Am Acad Dermatol"},{"key":"1880_CR37","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/bjo.79.11.1003","volume":"79","author":"MJ Elder","year":"1995","unstructured":"Elder\u00a0MJ, Dart\u00a0JK, Collin\u00a0R (1995) Inferior retractor plication surgery for lower lid entropion with trichiasis in ocular cicatricial pemphigoid. Br J Ophthalmol 79:1003\u20131006. https:\/\/doi.org\/10.1136\/bjo.79.11.1003","journal-title":"Br J Ophthalmol"},{"key":"1880_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2147\/TCRM.S1140","volume":"4","author":"AG Neff","year":"2008","unstructured":"Neff\u00a0AG (2008) Treatment strategies in mucous membrane pemphigoid. Ther Clin Risk Manag 4:617\u2013626. https:\/\/doi.org\/10.2147\/TCRM.S1140","journal-title":"Ther Clin Risk Manag"},{"key":"1880_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/PL00007877","volume":"238","author":"G Geerling","year":"2000","unstructured":"Geerling\u00a0G, Dart\u00a0JKG (2000) Management and outcome of cataract surgery in ocular cicatricial pemphigoid. Graefes Arch Clin Exp Ophthalmol 238:112\u2013118. https:\/\/doi.org\/10.1007\/PL00007877","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1880_CR40","first-page":"1024","volume":"15","author":"E Schmidt","year":"2017","unstructured":"Schmidt\u00a0E, Benoit\u00a0S, Kampik\u00a0D et\u00a0al (2017) Tibial bone keratoprosthesis: reversing blindness in mucous membrane pemphigoid. J\u00a0Dtsch Dermatol Ges 15:1024\u20131026","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"1880_CR41","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1055\/s-0043-111086","volume":"234","author":"G Geerling","year":"2017","unstructured":"Geerling\u00a0G, Hille\u00a0K (2017) Zum Stand der Keratoprothesen mit biologischer Haptik \u2013 Die D\u00fcsseldorf-Offenburger-Erfahrungen mit Osteo-Odonto- und Tibia-Keratoprothese. Klin Monbl Augenheilkd 234:763\u2013769. https:\/\/doi.org\/10.1055\/s-0043-111086","journal-title":"Klin Monbl Augenheilkd"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-023-01880-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-023-01880-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-023-01880-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T11:09:43Z","timestamp":1688728183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-023-01880-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1880"],"URL":"https:\/\/doi.org\/10.1007\/s00347-023-01880-y","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"15 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>R.\u00a0Ya\u00efci<\/b>: A.\u00a0Finanzielle Interessen: Referentenkostenerstattung f\u00fcr diverse Vortr\u00e4ge. Nicht in Zusammenhang mit der Publikation. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Facharzt f\u00fcr Augenheilkunde\u00a0\u2013 UKD; Wissenschaftliche Hilfskraft | Mitgliedschaften: DOG, BVA, SFO, EGS; alles nicht relevant f\u00fcr die Publikation. <b>M.\u00a0Roth<\/b>: A.\u00a0Finanzielle Interessen: M.\u00a0Roth gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Facharzt f\u00fcr Augenheilkunde, Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum D\u00fcsseldorf. Mitarbeiter in der Leitlinie zum Schleimhautpemphigoid. <b>G.\u00a0Geerling<\/b>: A.\u00a0Finanzielle Interessen: G.\u00a0Geerling gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Direktor der Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum D\u00fcsseldorf. Pr\u00e4sident\/Vizepr\u00e4sident der DOG und Mitarbeiter in der Leitlinie zum Schleimhautpemphigoid.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}